Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00231855 · ClinicalTrials.gov registry record · Phase 2

Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers

A Phase 2 study, sponsored by Montefiore Medical Center.

Completed
Registry status
Phase 2
Development phase
31
Enrollment target

NCT00231855 is a Phase 2 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 31 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00231855, a Phase 2 study, has completed, sponsored by Montefiore Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
31 participants
Enrollment target

Study Summary

The primary aim of this study is: * To determine the overall clinical response rate of weekly Topotecan and Taxotere in women with recurrent ovarian, primary peritoneal, endometrial and uterine cancers. The secondary aims of this study are: * To evaluate the safety and tolerability of the combination therapy with weekly Topotecan and Taxotere in patients with recurrent ovarian, primary peritoneal, endometrial or uterine cancers. * To determine the progression free survival and overall survival in women treated with weekly Topotecan and Taxotere in patients with recurrent ovarian, primary peritoneal, endometrial and uterine cancers who have been previously treated with chemotherapy and/or radiation therapy.

Interventions

  • DRUG Topotecan and Taxotere

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2004-11
Est. Completion 2007-03
Phase Phase 2

Sponsor

Montefiore Medical Center

345 total trials

What the Registry Record Tells You About NCT00231855

The ClinicalTrials.gov registry entry for NCT00231855 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Topotecan and Taxotere is the first listed.

NCT00231855 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00231855 about?

NCT00231855 is a clinical study titled "Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers". The primary aim of this study is: * To determine the overall clinical response rate of weekly Topotecan and Taxotere in women with recurrent ovarian, primary peritoneal, endometrial and uterine cancers. The secondary aims of this study are: * To evaluate the safety and tolerability of the combina...

What is the current status of trial NCT00231855?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2004-11. Estimated completion is 2007-03.

What interventions are being tested in trial NCT00231855?

The interventions under investigation include: Topotecan and Taxotere (DRUG).

Who is sponsoring clinical trial NCT00231855?

This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.